Career

2025 Recipients of CRI’s Sientific Awards

Collage photo of Alan Korman, Aviv Regev and Jeffrey Rathmell

Jul 27, 2025, 06:30

2025 Recipients of CRI’s Sientific Awards

Alicia Zhou, Chief Executive Officer at Cancer Research Institute (CRI), shared a post by Cancer Research Institute, adding:

“At the Cancer Research Institute (CRI), we believe progress in cancer immunotherapy begins with bold scientific ideas—and the people who have the courage to pursue them.

Today, we announced the 2025 recipients of CRI’s scientific awards, recognizing work that has fundamentally changed how we understand and treat cancer:

William B. Coley Award for Distinguished Research in Basic and Tumor Immunology

– Alan Korman, Ph.D., for his foundational role in developing immune checkpoint inhibitors such as ipilimumab and nivolumab—therapies that have redefined outcomes for patients with advanced cancers.
– Aviv Regev, Ph.D., for pioneering single-cell genomics and computational biology to map immune cell diversity and dynamics, opening new paths for precision immunotherapy.

Frederick W. Alt Award for New Discoveries in Immunology

– Jeffrey Rathmell, Ph.D., for groundbreaking research into immune cell metabolism and its implications for cancer and autoimmune disease.

Recognizing these scientists is more than a tradition—it is a reminder of what sustained investment in fundamental research can achieve. Their discoveries were not inevitable; they were the result of vision, persistence, and collaboration across academia and industry.

Please join me in congratulating this year’s honorees.”

Quoting Cancer Research Institute‘s post:

“CRI is pleased to announce the 2025 recipients of our highest scientific honors, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, and the Frederick W. Alt Award for New Discoveries in Immunology.

Dr. Alan Korman, Chief Scientific Officer of BlueSphere Bio, and Dr. Aviv Regev, Head and Executive Vice President of Genentech Research and Early Development at Genentech, will jointly receive the 2025 Coley Award in recognition of their transformational contributions to immunology. Dr. Jeffrey Rathmell, Chair of the Ben May Department for Cancer Research and Director of the Ludwig Center at the University of Chicago, has been named the recipient of the 2025 Frederick W. Alt Award for New Discoveries in Immunology.

“These extraordinary scientists represent the very best of cancer immunology and immunotherapy,” says CRI’s CEO, Alicia Zhou, PhD. “Their work is advancing not just our scientific understanding, but our ability to bring real, life-saving solutions to people facing cancer.”

More here.”

CRI CRI